Caris Life Sciences, Inc.

InocrasHealthcareUnited States

63% match

Inocras Inc. is a bioinformatics-led biotechnology company headquartered in San Diego, California. The firm utilizes whole genome data and proprietary artificial intelligence analytics to deliver curated genomic care.

GENINCODE PLCBiotechOxford, United Kingdom

63% match

GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.

NeoGenomics, Inc.NEO · BiotechFort Myers, United States

68% matchPublic

NeoGenomics, Inc. is a specialized clinical laboratory company headquartered in Fort Myers, Florida. It operates a network of CAP-accredited and CLIA-certified laboratories to provide comprehensive oncology testing and sample processing services.

Valius Health, Inc.HealthtechUnited States

67% match

Valius Health, Inc. provides comprehensive cancer diagnostic and tumor profiling services for patients and oncologists. The company analyzes tumor DNA, RNA, and proteins to identify actionable therapeutic targets and treatment options.

Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.